Lynparza meets primary endpoint in SOLO-3 trial
20 December 2018 07:05 GMT Lynparza meets primary endpoint in Phase III SOLO-3 trial for the treatment of relapsed BRCA-mutated advanced ovarian cancer AstraZeneca and MSD's Lynparza significantly improved objective response rate compared to chemotherapy in platinum-sensitive relapsed patients who had two or more prior lines of chemotherapy AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) today announced positive results from the randomised, open-label, controlled, Phase III SOLO-3 trial of Lynparza (olaparib) tablets in 266